Biomarker Testing Falls Short in NSCLC.

Two studies show that a large fraction of patients with non-small cell lung cancer isn't receiving biomarker testing. In one study, more than 20% of patients overall weren't tested before starting treatment. In the second, the testing rate was about 3% lower for African Americans than whites, and the rate of next-generation sequencing was about 10% lower.